Mechanism
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 29 amino acids of native GHRH — the bioactive fragment that contains all the GHRH receptor-binding activity of the full 44-amino-acid native molecule.
GHRH binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, activating Gs-coupled signaling (adenylate cyclase → cAMP) and stimulating GH synthesis and secretion. Native GHRH has a half-life of ~7 minutes; sermorelin extends this slightly to ~10–20 minutes — still short, producing a pulse rather than sustained stimulation.
The clinical premise (in pediatric GH deficiency): stimulating endogenous GH secretion is more physiologic than recombinant GH replacement — preserves the natural pulsatile secretion pattern, requires intact pituitary function, theoretically lower risk of receptor desensitization. Empirically, sermorelin and recombinant GH produced comparable growth velocity outcomes in pediatric trials.
The clinical premise (off-label adult): the same pulsatile GH pattern but in healthy or somewhat-deficient adults. Modest GH/IGF-1 elevation is hypothesized to produce body-composition effects (lean mass increase, fat decrease), sleep quality improvements, and anti-aging effects.
Same mechanistic family as CJC-1295 (without DAC), which is essentially a slightly-engineered variant of sermorelin’s core structure.
What the evidence shows
Pediatric GH deficiency (1990s pivotal trials): Multiple RCTs in pediatric GHD established sermorelin as effective for increasing growth velocity, comparable to recombinant GH. This was the basis for Geref approval. The drug was used clinically through the 2000s before commercial withdrawal.
Adult GHD (small trials): Some Phase 2 work in adult GHD, but the indication never had Phase 3 confirmatory data and never reached approval in adults.
Off-label adult body-composition / anti-aging / sleep:
- No published RCTs at the doses typically used in compounding pharmacy or gray-market protocols
- Anecdotal reports of subjective sleep improvements and modest body-composition changes
- Same evidence pattern as CJC-1295 — mechanism is sound, efficacy in non-clinical-indication populations is uncharacterized
Why this matters for the verdict: Sermorelin’s pediatric GHD evidence is real but doesn’t transfer to adult off-label use. The drug is widely sold by compounding pharmacies and gray-market vendors for indications it was never trialed for. Investigational is the honest verdict.
Dosing literature
There is no current approved dose. Compounding pharmacy and gray-market protocols typically use:
- Subcutaneous, pre-sleep: 100–500 mcg/day
- Frequency: Single daily dose or split into two
- Cycle structure: Often 3–6 month courses with breaks; some protocols use continuous daily dosing for extended periods
The pre-sleep timing is mechanistically reasonable — overnight is when natural GH secretion peaks, and amplifying that pulse without disrupting circadian rhythm is the pharmacological premise.
We do not endorse a dose. The numbers above describe what’s used, not what’s recommended.
Risks and adverse events
Reported in clinical and gray-market use:
- Injection site reactions
- Flushing, occasional warmth post-injection
- Transient headache
- Dizziness, mild
- Insulin resistance with sustained use (chronic GH elevation is mildly diabetogenic)
Less common:
- Joint pain or carpal tunnel symptoms (class-typical of GH-axis manipulation)
- Edema
- Tachyphylaxis with very-prolonged daily use
Theoretical / long-term concerns:
- Cumulative IGF-1 elevation — same cancer-promotion concerns flagged for IGF-1 LR3 and CJC-1295; sermorelin’s elevation is generally more modest because the GH pulses are smaller, but cumulative chronic exposure is what matters
- Unknown long-term effects of pharmacologic GH-axis stimulation in metabolically healthy adults
- Tachyphylaxis with chronic continuous use — receptor desensitization can diminish response over months
Quality concerns specific to gray-market product:
The 29-amino-acid sequence is straightforward to synthesize. Compounding pharmacy preparations have variable QC; gray-market vendor product has the typical identity-and-purity concerns documented across the peptide research-chemical channel.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Not approved | Geref withdrawn 2008; available through compounding pharmacies under section 503A |
| European Union | Not approved | |
| United Kingdom | Not approved | |
| Australia | Schedule 4 | Prescription-only; not commercially available |
| WADA | Prohibited (S2 — Peptide Hormones) | Banned in competitive sport at all times |
The FDA in 2023 listed sermorelin among substances that compounding pharmacies could not produce under section 503A, with limited exceptions. Access has narrowed.
Where to get it
The legitimate access path for clinically-relevant use cases is via a clinician with experience in adult endocrinology and a compounding pharmacy operating under appropriate regulatory authority — and only for indications where the clinical evidence supports use.
We do not route readers to gray-market sources for sermorelin. The off-label “anti-aging” use is not supported by the kind of evidence we’d require. (See How we make money.)
References (selected)
- Walker RF et al. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006. PubMed
- Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. N Engl J Med 1985 — early pivotal study.
- Vance ML et al. Pulsatile growth hormone-rel
Quick Facts
| Also Known As | GRF (1-29), GHRH (1-29), Growth hormone-releasing hormone (1-29), Geref |
|---|---|
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg |
| Molecular Formula | C149H246N44O42S |
| Molecular Weight | 3357.9 Da |
| PubChem CID | 16132413 |
Research Parameters
| Half-Life | ~10-20 minutes |
|---|---|
| Stability | Lyophilized powder is stable at recommended storage conditions for extended periods. After reconstitution with bacteriostatic water, the solution is typically stable for 14-28 days when stored refrigerated at 2-8°C. |
| Solubility | Bacteriostatic Water (0.9% Benzyl Alcohol) or Sterile Water for injection. |
| Vial Size | 2 mg |
| Storage (Lyophilized) | -20°C, protected from light and moisture. |
| Storage (Reconstituted) | 2-8°C (refrigerated), protected from light. Use within the stability period indicated for the reconstitution solvent. |
| Typical Research Dose | 0.5-2.0 mcg/kg |
| Cycle Parameters | In research, typically administered as a daily subcutaneous injection, often in the evening. Study protocols vary, with common durations ranging from several weeks to 6 months or longer. |
| Amino Acid Count | 29 |
Mechanism of Action
Sermorelin acts as a potent agonist at the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary. Binding initiates a cascade of intracellular signaling events that culminate in the synthesis and secretion of endogenous growth hormone.
GHRHR Activation: Sermorelin binds with high affinity to the GHRHR, a G-protein coupled receptor (GPCR) primarily expressed on pituitary somatotrophs.
cAMP/PKA Pathway: Receptor activation stimulates the Gs alpha subunit, which subsequently activates adenylate cyclase. This increases intracellular cyclic adenosine monophosphate (cAMP) levels, activating protein kinase A (PKA). PKA phosphorylates key transcription factors, notably cAMP response element-binding protein (CREB), which translocates to the nucleus.
Gene Transcription: Phosphorylated CREB binds to cAMP response elements (CREs) in the promoter region of the GH gene (GH1), driving the transcription of growth hormone mRNA.
GH Synthesis and Secretion: The translated GH is packaged into secretory vesicles. The cAMP/PKA pathway and an accompanying influx of calcium ions facilitate the exocytosis of these vesicles, resulting in the pulsatile release of endogenous GH into the systemic circulation.
Feedback Regulation: The released GH exerts negative feedback on its own secretion by stimulating the production of somatostatin from the hypothalamus. Importantly, sermorelin's action remains subject to this inhibitory feedback, unlike exogenous GH administration, which can bypass it.
Research Applications
Endocrine and Aging Research: Sermorelin has been extensively studied as a diagnostic agent and research tool for assessing pituitary GH reserve in conditions like growth hormone deficiency (GHD). In aging research, it is used to investigate the somatopause—the age-related decline in GH secretion—and its potential links to decreased muscle mass, increased adiposity, and reduced bone density. Studies explore whether restoring a more youthful pulsatile GH pattern can mitigate these physiological changes.
Metabolic Research: Research investigates sermorelin's role in metabolism, focusing on its ability to influence lipolysis and improve body composition by reducing visceral adipose tissue. Studies examine its effects on insulin sensitivity and glucose metabolism, given the complex interplay between GH and insulin, to understand potential benefits in metabolic syndrome.
Body Composition and Physical Function: Preclinical and clinical studies have evaluated sermorelin's impact on increasing lean body mass and muscle strength, particularly in elderly populations or those with catabolic conditions. Research aims to determine if GH stimulation can improve physical function, exercise capacity, and recovery without the adverse effects associated with supraphysiological GH doses.
Bone Health: The anabolic effects of GH on bone are mediated indirectly via insulin-like growth factor 1 (IGF-1). Research with sermorelin examines its potential to increase bone mineral density and bone turnover markers, offering insights into therapeutic strategies for osteoporosis and fracture healing.
Safety & Side Effects
In clinical research, sermorelin is generally well-tolerated. The most commonly reported side effects are local and mild, including redness, swelling, or pain at the injection site. Systemic side effects are less frequent but can include headache, flushing, dizziness, and nausea. Due to its mechanism of action, side effects related to GH excess (e.g., arthralgia, edema, carpal tunnel syndrome) are theoretically possible but reported far less frequently than with direct GH administration, likely due to the preservation of feedback loops. Anecdotal reports from non-clinical use sometimes mention transient hunger or tiredness. Theoretical concerns include the potential impact on glucose tolerance and the risk of promoting the growth of pre-existing malignancies, as GH and IGF-1 are growth factors.
Dosage Information
This information is derived from published research protocols and is for research purposes only. Typical research doses in human studies range from 0.5 to 2.0 mcg/kg body weight. The most common route of administration is subcutaneous injection. In research settings, it is typically administered once daily, often at bedtime to mimic the natural nocturnal surge of GH. Study durations have varied widely, from single-dose diagnostic tests to long-term investigations lasting 6 months to a year or more.
References
Thorner, M.O., et al. 'Sermorelin (GRF 1-29 NH2) in the treatment of delayed growth hormone release.' Acta Paediatrica Scandinavica. Supplement, 1989.
Corpas, E., et al. 'Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-I in old men.' Journal of Gerontology, 1993.
Khare, A., et al. 'Growth hormone (GH) responses to GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), and clonidine in young and elderly subjects.' Metabolism, 1995.
Chapman, I.M., et al. 'Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.' Journal of Clinical Endocrinology & Metabolism, 1996.
Vance, M.L., & Thorner, M.O. 'Some clinical considerations of growth hormone-releasing hormone.' Endocrine Reviews, 1988.
Bowers, C.Y., et al. 'On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.' Endocrinology, 1984.